NORM PPCI

  • Research type

    Research Study

  • Full title

    NO Reflow PhenoMenon and comparison to the normal flow population post Primary Percutaneous Coronary Intervention for ST elevation myocardial infarction

  • IRAS ID

    184221

  • Contact name

    Jennifer A Rossington

  • Contact email

    jennifer.rossington@hey.nhs.uk

  • Sponsor organisation

    Hull and East Yorkshire NHS Trust

  • Duration of Study in the UK

    0 years, 6 months, 1 days

  • Research summary

    Heart attacks which present with particular heart tracing changes are a result of a clot completely blocking one of the hearts main blood vessels. This prevents the blood from delivering oxygen to the heart muscle, and can result in death of the heart muscle unless treated. The treatment recommended by the National Institute of Health and Care Excellence (NICE) is Primary Percutaneous Coronary Intervention (PPCI). This is the urgent procedure you underwent on admission and involves a wire, balloon and probable stent insertion into the blocked heart artery via a blood vessel in your arm or leg. The aim is to open the heart blood vessel (artery) and restore blood flow to the muscle.

    In some cases despite opening up of the main heart vessel involved, the blood flow beyond the blockage is reduced which is a result of multiple processes; including clot travelling down the vessel, chemicals released by damaged cells and swelling of the surrounding muscle. This is known as no-reflow phenomenon.

    Patients with this condition are at higher risk of heart muscle death, which can prevent the heart pump from working properly. There are treatments available to improve the flow but these are always provided after no-reflow phenomenon is seen during PPCI. Ideally preventative treatment would be optimum, however at present which patients are at the highest risk is not completely understood.

    In this study we hope to gain a better understanding of no reflow phenomenon by looking at all patients presenting with heart attacks requiring PPCI. We plan to observe the frequency of no reflow phenomenon and compare multiple aspects of patient presentation, such as other medical complaints and features of the blockage, to see if we can find risk factors which would help us predict when it may occur.

  • REC name

    Yorkshire & The Humber - Bradford Leeds Research Ethics Committee

  • REC reference

    15/YH/0360

  • Date of REC Opinion

    19 Oct 2015

  • REC opinion

    Further Information Favourable Opinion